SRL, but not TAC effectively inhibited the differentiation of B cells into plasma cells.

<p>Purified CD19⁺ B cells were cultured as in Figs <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0129658#pone.0129658.g001" target="_blank">1</a> and <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0129658#pone.0129658.g002" target="_blank">2</a>. <b>(A)</b> A representative experiment showing flow cytometric profile indicative of putative plasma cells (CD19^low) in proliferated B cells (gated on viable lymphocytes; see <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0129658#pone.0129658.g001" target="_blank">Fig 1A</a>). <b>(B)</b> The mean ± SD percentage of such CD19^low B cells from 4 different independent experiments. <b>(C)</b> Mean ± SD (n = 4) percentage of CD19^lowCD38⁺⁺ plasmablasts, CD19^lowCD138⁺ plasma cells, Blimp1⁺PAX5^- cells and CD138⁺Blimp1⁺ cells in the proliferating CD19^low cells. *p < 0.05, **p < 0.01. CTRL, control; TAC, 6 ng/ml TAC; SRL, 6 ng/ml SRL.